The first annual Pulmonary Horizons conference to educate, and train all the leading experts including patients with COPD . Please click on the link http://www.pulmonaryhorizons.com to see more information. It’s being held in beautiful San Diego at the great Doubletree Resort on August 16-17, 2014.
ICC GLOBAL ACTIVITIES
Thanks for your support of COPD patients and the International COPD
Coalition (ICC) in advocating for COPD and other respiratory diseases.
Please help further ICC’s mission by joining us on Twitter. ICC is tweeting
information about COPD advocacy, the latest research on early diagnosis, and
other thought-provoking issues in our ICC Column in the Journal of Thoracic
Disease, where we reach out to the respiratory community!
Please follow us at https://twitter.com/intlCOPD and add your voice to the
conversation. We want to hear about your activities and join us in our
work to help COPD patients and other shared respiratory causes!
We are partnering in covering respiratory and other important medical
stories with Health Care Vlogs (www.healthcarevlogs.com) an open access
medical video network.
Click this LINK to view the stories on early COPD diagnosis and how it
offers new opportunities to nip the process in the bud! See Prof. Nanshan
Zhong (ICC Executive Committee Chair), Dr. Zhu Chen, and Prof. Chunxue Bai
and the landmark research. Currently 89 study centers are starting in
Join us on Health Care Vlogs for the stories that make a difference in our
Larry Grouse, MD, PhD
Executive Director, ICC
BROADWAY’S BEST GATHER TO RAISE FUNDS AND AWARENESS FOR THE PULMONARY FIBROSIS FOUNDATION
Anything Goes’ Julie Halston, Robert Creighton, and Surprise Guest Joel Grey Join Legendary Belter Darlene Love for Second Annual Broadway Belts for PFF!
NEW YORK, February 28, 2012 /PRNewswire/ — With honors ranging from the Rock’n'Roll Hall of Fame to the Tony Awards, Broadway’s best performers gathered Monday night to raise awareness of the rare disease, pulmonary fibrosis, and honor the memory of Associated Press theater critic, Michael Kuchwara. Hosted by award-winning actress and devoted Pulmonary Fibrosis Foundation (PFF) advocate Julie Halston, Broadway Belts for PFF! returned to Birdland in New York City for a second successful year. The event raised almost $50,000 to benefit the Foundation.
Sirius Satellite Radio’s Seth Rudetsky opened the show with an amusing monologue about belting and his favorite belters, including last year’s surprise guest Liza Minnelli. Broadway stars showcased their belting abilities under the musical direction of Jesse Kissel and returning director Carl Andress. The all-star cast included: Tony nominees Adam Pascal (Memphis) and Andrew Rannells (The Book of Mormon), Robert Creighton (Anything Goes), Lindsay Mendez (Godspell), Betsy Wolfe (Encores! Merrily We Roll Along), Heidi Blickenstaff (Now. Here. This., [title of show]), and Julia Murney (Queen of the Mist/Wicked). In a touching moment of remembrance, theater critic Adam Feldman took the stage and gave a heartfelt tribute to his friend and colleague, Michael Kuchwara
The evening’s surprise guest was famed Joel Grey, currently starring as Moonface Martin in the Broadway revivial of Anything Goes. He joined the stage with fellow Anything Goes cast member Robert Creighton to sing a duet of “Give My Regards to Broadway” and then an impromptu rendition of “Wilkommen” from his Tony Award
and Oscar Award winning role as the Master of Ceremonies in Cabaret. The evening culminated with the spectacular Darlene Love delighting the audience with “Today I Met the Man I’m Going to Marry” and “I Know Where I Have Been.” The entire cast joined Ms. Love on stage for an all-star, grand finale of the “Da Doo Ron Ron.”
“The success of Broadway Belts for PFF! is a testament to the hard work of Julie Halston and her amazing team,” said the PFF’s Chief Operating Officer, Patti Tuomey. “Their efforts amplify the Pulmonary Fibrosis Foundation’s mission, increasing awareness on Broadway and beyond. By raising almost $50,000 through this event, Julie makes our goal of finding a cure that much more feasible.”
Julie Halston, currently starring in Anything Goes, became the leading spokesperson for the PFF after her husband, broadcaster Ralph Howard, received a lung transplant due to pulmonary fibrosis. Ms. Halston hopes that the awareness created by Broadway Belts for PFF! will assist others affected by the disease.
“Five years ago, I had never even heard of pulmonary fibrosis. First my husband was diagnosed and then I lost my close friend Michael to the disease,” said Halston. “Now, I want to make sure everyone knows about the Pulmonary Fibrosis Foundation, so that no one with the disease has to go through this alone. Together we can raise awareness and fund the research that will bring us closer to finding a cure.”
The PFF’s President and Chief Executive Officer, Daniel M. Rose, MD, emphasized the importance of funding research, as well as raising awareness. “With no FDA-approved treatment or cure for pulmonary fibrosis, funding research is a vital element of the Pulmonary Fibrosis Foundation’s efforts,” said Dr. Rose. “Over the last ten years, pulmonary fibrosis research has greatly advanced and the Foundation has an increasingly clear picture of what needs to be done to support researchers, doctors, and patients.”
The Pulmonary Fibrosis Foundation would like to thank this year’s Broadway Belts for PFF! Presenting Sponsor, the Doug and Gay Lane Charitable Foundation and Director’s Circle Sponsor, Broadway Cares/Equity Fights AIDS. The Foundation would also like to thank the following Broadway Partner Sponsors: Margo Lion; The Nederlander Organization; Daryl Roth; Richard Rothberg and Gersowitz, Libo and Korek, P.C. ESQS; and Thomas Schumacher.
All funds raised by the event will go toward the Pulmonary Fibrosis Foundation’s Michael Kuchwara Fund for Idiopathic Pulmonary Fibrosis Research, Education, and Advocacy in honor of the late Associated Press theater critic and reporter. Mr. Kuchwara passed away from idiopathic pulmonary fibrosis in May of 2010.
For more information on the Pulmonary Fibrosis Foundation, or to make a donation, please visit www.pulmonaryfibrosis.org.
Having to live with an external oxygen source is no fun for people with COPD. The patients who require supplemental oxygen often are tethered to a heavy gas tank or an almost as heavy oxygen concentrator. There are portable concentrators on the market, but the lightweight ones designed for travel usually only offer pulsed oxygen delivery, effectively leaving a lot of people left with heavier devices that have to be wheeled around.
Philips Respironics has developed the SimplyGo highly portable oxygen concentrator that weighs ten pounds (4.5 Kg) and offers both pulsed and continuous oxygen delivery. This means that almost anyone requiring external oxygen can go fishing with the nephew instead of being stuck at home. Just don’t get the oxygen delivery tube tangled around the fishing line.
Like all POCs, SimplyGo delivers pulse dose oxygen—a burst of oxygen triggered when the user starts to take a breath. But SimplyGo is different from smaller devices because it is also capable of delivering oxygen continuously, similar to stationary concentrators used at home. With oxygen output of up to four times that of some lightweight POCs, SimplyGo can meet the portable needs of nearly all oxygen users including those who are highly active or require continuous flow.
Philips designed its latest portable oxygen concentrator with a long-life compressor, high-impact resistant design and oversized cart wheels in order to be rugged and easy-to-use. SimplyGo was tested and subjected to extreme conditions, including impacts, vibrations and temperatures, to deliver reliable performance day in and day out in real-life conditions experienced by oxygen users.
SimplyGo comes with an attractive, functional carrying case; fold-up mobile cart; intuitive, easy-to-read screen; and detachable accessory bag. A lightweight and compact battery adds to its portability. Extra batteries are available and can fit easily into the zippered pouch on the carrying case or accessories bag for extended use.
Additionally, two-, three-, or five-year warranties and flexible service programs are offered with SimplyGo to give homecare providers a variety of options to meet their individual business needs. SimplyGo’s design and comprehensive service tools also allow technicians to perform work right on site, if they choose.
Press release: Philips Respironics introduces portable oxygen concentrator that meets the needs of nearly all oxygen users
Product page: Philips Respironics SimplyGo…
Article Date: 31 Oct 2011 – 1:00 PDT
Researchers at Weill Cornell Medical College say they have taken an
important step forward in their quest to “turn on” lung regeneration — an
advance that could effectively treat millions of people suffering from
In the journal Cell, the research team reports that they have uncovered
the biochemical signals in mice that trigger generation of new lung
alveoli, the numerous, tiny, grape-like sacs within the lung where oxygen
exchange takes place. Specifically, the regenerative signals originate
from the specialized endothelial cells that line the interior of blood
vessels in the lung.
While it has long been known that mice can regenerate and expand the
capacity of one lung if the other is missing, this study now identifies
molecular triggers behind this process, and the researchers believe these
findings are relevant to humans.
“Several adult human organs have the potential upon injury to regenerate
to a degree, and while we can readily monitor the pathways involved in the
regeneration of liver and bone marrow, it is much more cumbersome to study
the regeneration of other adult organs, such as the lung and heart,” says
the study’s lead investigator, Dr. Shahin Rafii, who is the Arthur B.
Belfer Professor of Genetic Medicine and co-director of the Ansary Stem
Cell Institute at Weill Cornell Medical College.
“It is speculated, but not proven, that humans have the potential to
regenerate their lung alveoli until they can’t anymore, due to smoking,
cancer or other extensive chronic damage,” says Dr. Rafii, who is also an
investigator at the Howard Hughes Medical Institute. “Our hope is to take
these findings into the clinic and see if we can induce lung regeneration
in patients who need it, such as those with chronic obstructive pulmonary
“There is no effective therapy for patients diagnosed with COPD. Based on
this study, I envision a day when patients with COPD and other chronic
lung diseases may benefit from treatment with factors derived from lung
blood vessels that induce lung regeneration,” states Dr. Ronald G.
Crystal, who is a co-author of this study and professor of pulmonary and
genetic medicine at Weill Cornell.
Dr. Rafii and his researchers had previously uncovered growth factors that
control regeneration in the liver and bone marrow, and in both cases, they
found that endothelial cells produce the key inductive growth factors,
which they defined as “angiocrine factors.” In the current lung study,
they discovered the same phenomenon — that blood vessel cells in the
lungs jump-start regeneration of alveoli. “Blood vessels are not just the
inert plumbing that carries blood. They actively instruct organ
regeneration,” says Dr. Rafii. “This is a critical finding. Each organ
uses different growth factors within its local vascular system to promote
To conduct this study, Dr. Bi-Sen Ding, a postdoctoral fellow in Dr.
Rafii’s lab and the first author of this paper, removed the left lungs of
mice and studied the biochemical process of subsequent regeneration of the
remaining right lung. Previous pioneering work by Dr. Crystal had shown
that when the left lung of mice is removed, the right lung regenerates by
80 percent, effectively replacing most of the lost alveoli. “This
regeneration process also restores the physiological respiratory function
of the lungs, which is mediated by amplification of various epithelial
progenitor cells and regeneration of the alveolar sacs,” says Dr. Ding.
“This regenerative phenomenon, however, only occurs after a trauma that
abruptly reduces lung mass. Then the specific subsets of blood vessels in
the remaining lung receive a message to start to repopulate alveoli, and
our job was to find that signal,” says Dr. Daniel Nolan, a senior
scientist in this project who developed methods to characterize the lung
blood vessel cells.
The scientists found that removal of the left lung activates receptors on
lung endothelial cells that respond to vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (FGF-2). Activation of these
receptors promotes the rise of another protein, matrix
metalloproteinase-14 (MMP14). The researchers discovered that MMP14, by
releasing epidermal growth factors (EGF), initiates the generation of new
When the investigators disabled receptors of VEGF and FGF-2 specifically
in the endothelial cells of the mice, the right lung would not regenerate.
The defect in the lung regeneration was found to be due to the lack of
MMP14 generation from the blood vessels. Remarkably, when these mice
received an endothelial cell transplant from a normal mouse, the
production of MMP14 was restored, triggering the regeneration of
“The recovery of lung function and lung mechanics by transplantation of
endothelial cells that stimulate MMP14 production may be valuable for
designing novel therapies for respiratory disorders,” says Dr. Stefan
Worgall, who helped with the functional lung studies in this project.
“This study will also help us understand mechanisms for repair in the
growing lungs of infants and children,” he adds. Dr. Worgall is associate
professor of pediatrics and genetic medicine and distinguished associate
professor of pediatric pulmonology.
Given MMP14′s role, Dr. Rafii classifies it as a crucial “angiocrine”
signal — a lung endothelial specific growth factor responsible for
alveolar regeneration. Dr. Rafii’s team also seeks to reveal the
initiation signals resulting in the activation of lung blood vessels.
“Changes in local blood flow and biomechanical forces in the remaining
lung after removal of the left lung could certainly be one of the
initiation cues that induce endothelial activation,” says Dr. Sina
Rabbany, who is a co-senior author of this study and a professor of
bioengineering at Hofstra University and adjunct associate professor of
genetic medicine and bioengineering in medicine at Weill Cornell.
The researchers will next determine if MMP14 and other as-yet unrecognized
angiocrine factors are responsible for lung regeneration in humans as well
as mice. “We believe the same process goes on in humans, although we have
no direct evidence yet,” says Dr. Ding. The study’s authors theorize that
patients with COPD (a disorder most often caused by chronic smoking) have
so much damage to their lung endothelial cells that they no longer produce
the proper inductive signals. “We know
smoking damages lungs, but lungs may continue to regenerate alveoli,” says
Dr. Koji Shido, a co-author of this study. “But at certain point,
significant injury to the endothelial cells could impair their capacity to
support lung regeneration.”
“Perhaps replacement of angiocrine factors, or transplantation of normal
lung endothelial cells derived from pluripotent stem cells, could restore
lung regeneration” speculates Dr. Zev Rosenwaks, who is the director of
the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
at Weill Cornell, and a co-author of this study. “Currently, we are
generating pluripotent stem cells derived from patients with genetic
pulmonary disorders to identify potential pathways, which may ultimately
enhance our understanding of how lung endothelial cells may improve lung
function in these patients.”
Are you a COPD patient who has undergone surgery? If so, after reading this article, you will have an opportunity to share about what precautions you took before you were administered general anesthesia.
The combination of COPD and anesthesia can be risky business. In fact, the long-term survival rate of COPD patients with severe airway disease who have any type of major surgery is poor. There is also a significant risk of postoperative complications, especially within the lungs. But does this mean that COPD patients should never have surgery?